Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
The Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. Photograph: James Manning/PAView image in fullscreenThe Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. It’s one of the greatest concerns that people have,” she said.“But it’s still a very rare condition, while the other conditions these medications treat are very common, like heart attacks, stroke and kidney disease.
- ▪The Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic op
- ▪Photograph: James Manning/PAView image in fullscreenThe Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of t
- ▪It’s one of the greatest concerns that people have,” she said.“But it’s still a very rare condition, while the other conditions these medications treat are very common, like heart attacks, stroke and kidney disease.
The Guardian — World publishes from United Kingdom and files mainly under world. We currently carry 2,034 of its stories.
Opening excerpt (first ~120 words) tap to expand
The Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. Photograph: James Manning/PAView image in fullscreenThe Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — World.
Discussion
0 commentsMore from The Guardian — World
